Pipeline

BioArctic’s portfolio has projects in several focus areas and in various phases from discovery through clinical development.

Antibody Project BrainTransporter™
Project
Indication
Partner
Research
Preclinical
Phase 1
Phase 2
Phase 3
Reg. application
Market
Antibodies with amyloid-beta
Lecanemab (IV)1
Alzheimer’s disease
Eisai
Lecanemab (s.c)2
Alzheimer’s disease
Eisai
Lecanemab
(presymptomatic treatment)
Alzheimer’s disease
Eisai
Lecanemab back-up
Alzheimer’s disease
Eisai
BAN1503
(PyroGlu Aß)
Alzheimer’s disease
BMS3
BAN2803
(PyroGlu Aß with BT)5
Alzheimer's disease
BMS3
BAN2802
Alzheimer's disease
Eisai4
Antibodies targeting alpha-synuclei
Exidavnemab
(a-synuclein)
Parkinson's disease, MSA
BAN2238
(a-synuclein with BT)
Parkinson's disease, MSA
PD-BT2278
(α-synuklein with BT+)
Parkinson’s disease, MSA
Antibodies targeting TDP-43
BAN3014
(TDP-43)
ALS
ND-BT3814
(TDP-43 with BT)
ALS
Antibodies targeting Huntington
HD-BT4801
(HTT with BT)
Huntington's disease
Other
GD-BT6822
(Gcase with BT)
Gaucher disease
ND-BT8825
Neurodegeneration
Novartis
Technology- and modality development
Antibody Project [ Alzheimer’s disease ]
Project
Lecanemab (IV)1
Indication
Alzheimer’s disease
Partner
Eisai
Research Preclinical Phase 1 Phase 2 Phase 3 Reg. application Market
Antibody Project [ Alzheimer’s disease ]
Project
Lecanemab (s.c)2
Indication
Alzheimer’s disease
Partner
Eisai
Research Preclinical Phase 1 Phase 2 Phase 3 Reg. application Market
Antibody Project [ Alzheimer’s disease ]
Project
Lecanemab
(presymptomatic treatment)
Indication
Alzheimer’s disease
Partner
Eisai
Research Preclinical Phase 1 Phase 2 Phase 3 Reg. application Market
Antibody Project [ Alzheimer’s disease ]
Project
Lecanemab back-up
Indication
Alzheimer’s disease
Partner
Eisai
Research Preclinical Phase 1 Phase 2 Phase 3 Reg. application Market
Antibody Project [ Alzheimer’s disease ]
Project
BAN1503
(PyroGlu Aß)
Indication
Alzheimer’s disease
Partner
BMS3
Research Preclinical Phase 1 Phase 2 Phase 3 Reg. application Market
BrainTransporter™ [ Alzheimer's disease ]
Project
BAN2803
(PyroGlu Aß with BT)5
Indication
Alzheimer's disease
Partner
BMS3
Research Preclinical Phase 1 Phase 2 Phase 3 Reg. application Market
BrainTransporter™ [ Alzheimer's disease ]
Project
BAN2802
Indication
Alzheimer's disease
Partner
Eisai4
Research Preclinical Phase 1 Phase 2 Phase 3 Reg. application Market
Antibody Project [ Parkinson's disease, MSA ]
Project
Exidavnemab
(a-synuclein)
Indication
Parkinson's disease, MSA
Research Preclinical Phase 1 Phase 2 Phase 3 Reg. application Market
BrainTransporter™ [ Parkinson's disease, MSA ]
Project
BAN2238
(a-synuclein with BT)
Indication
Parkinson's disease, MSA
Research Preclinical Phase 1 Phase 2 Phase 3 Reg. application Market
BrainTransporter™ [ Parkinson’s disease, MSA ]
Project
PD-BT2278
(α-synuklein with BT+)
Indication
Parkinson’s disease, MSA
Research Preclinical Phase 1 Phase 2 Phase 3 Reg. application Market
Antibody Project [ ALS ]
Project
BAN3014
(TDP-43)
Indication
ALS
Research Preclinical Phase 1 Phase 2 Phase 3 Reg. application Market
BrainTransporter™ [ ALS ]
Project
ND-BT3814
(TDP-43 with BT)
Indication
ALS
Research Preclinical Phase 1 Phase 2 Phase 3 Reg. application Market
BrainTransporter™ [ Huntington's disease ]
Project
HD-BT4801
(HTT with BT)
Indication
Huntington's disease
Research Preclinical Phase 1 Phase 2 Phase 3 Reg. application Market
BrainTransporter™ [ Gaucher disease ]
Project
GD-BT6822
(Gcase with BT)
Indication
Gaucher disease
Research Preclinical Phase 1 Phase 2 Phase 3 Reg. application Market
BrainTransporter™ [ Neurodegeneration ]
Project
ND-BT8825
Indication
Neurodegeneration
Partner
Novartis
Research Preclinical Phase 1 Phase 2 Phase 3 Reg. application Market
BrainTransporter™
Project
Technology- and modality development
Research Preclinical Phase 1 Phase 2 Phase 3 Reg. application Market

    1. Intravenous treatment
    2. Subcutaneous treatment
    3. A license agreement was signed with Bristol Myers Squibb on December 19, 2024, and entered into force on February 20th, 2025.
    4. Research evaluation agreement with Eisai
    5. BrainTransporter